Table 1.
T- and B-cell subset phenotyping.
| Patient T1 |
Controls SM (on fingolimod) |
Patient T2 |
Controls SM (washouta) |
Patient T1 |
Controls SM (on fingolimod) |
Patient T2 |
Controls SM (washout) |
|
|---|---|---|---|---|---|---|---|---|
| % | range (%) | % | range (%) | μL | range (μL) | μL | range (μL) | |
| CD3+ | 75.1 | 40.1–76.4 | 85.7 | 67.8–81.0 | 198 | 119–1090 | 568 | 746–1313 |
| CD3+CD4+ | 44.8 | 5.3–34.8 | 59.6 | 20.5–43.8 | 118 | 43–290 | 395 | 332–573 |
| CD3+CD4+CD45RA+CCR7+CD31+ (RTE)b | 2.6 | 0.2–3.6 | 6.8 | 1.7–8.2 | 3 | 0–3 | 27 | 7–47 |
| CD3+CD4+CD45RA+CCR7+ (naïve) | 4.8 | 0.5–6 | 11.1 | 5.6–13.3 | 6 | 0–10 | 44 | 23–76 |
| CD3+CD4+CD45RA-CCR7+ (TCM) | 7.5 | 1.8–17.7 | 21.2 | 53.6–62.4 | 9 | 1–25 | 84 | 191–307 |
| CD3+CD4+CD45RA-CCR7- (TEM) | 74.8 | 15.7–75.6 | 55.9 | 30.1–35.0 | 88 | 12–80 | 221 | 116–184 |
| CD3+CD4+HLA-DR+ | 2.9 | 2.8–9.4 | 11.1 | na | 3 | 2–12 | 44 | na |
| Regulatory T cells (CD3+CD4+CD25highCD127low/) | 2.2 | 1.1–9.1 | 5.4 | 8.3–10.5 | 3 | 1–8 | 21 | 30–51 |
| CD3+CD8+ | 24.7 | 12.5–65.1 | 22.2 | 21.9–56.9 | 65 | 37–928 | 147 | 242–922 |
| CD3+CD8+CD45RA+CCR7+ (naïve) | 4.1 | 0.3–2.8 | 9.3 | 4.0–12.0 | 3 | 1–4 | 14 | 18–50 |
| CD3+CD8+CD45RA-CCR7+ (TCM) | 2.2 | 0.2–2.6 | 2.9 | 9.9–10.9 | 1 | 0–5 | 4 | 24–91 |
| CD3+CD8+CD45RA-CCR7- (TEM) | 16.4 | 11.3–31.7 | 26.6 | 33.0–51.2 | 11 | 4–239 | 39 | 124–406 |
| CD3+CD8+CD45RA+CCR7- (TEMRA) | 77.3 | 63.8–85.7 | 61.3 | 31.4–44.2 | 50 | 100–683 | 90 | 76–388 |
| CD3+CD8+HLA-DR+ | 4.5 | 1.7–12.6 | 9.9 | na | 3 | 2–16 | 15 | na |
| CD4/CD8 ratio | 1.81 | 0.1–2.0 | 2.7 | 0.4–2.0 | – | – | – | – |
| CD3-CD56+CD3-CD16+ (NK cells) | 22.1 | 21.5–55.4 | 11 | 14.8–24.7 | 58 | 164–307 | 73 | 213–272 |
| CD19+ | 2.6 | 1.9–4.3 | 2.8 | 4.1–7.3 | 7 | 13–27 | 20 | 66–81 |
| CD38++CD10+ (RBE) | 8.8 | 9.5–39-7 | 9.6 | 2.9–34.4 | 1 | 1–11 | 2 | 2–27 |
| CD19+CD10-CD27-IgD+ (naive) | 28.5 | 32.1–52.3 | 40.9 | 40.1–48.4 | 2 | 6–11 | 8 | 29–37 |
| CD19+CD27+IgD+IgM+ (memory unswitched) | 10.6 | 2.9–16.1 | 14.2 | 7.5–8.8 | 1 | 1–4 | 3 | 5–7 |
| CD19+CD27+IgD-IgM- (memory switched) | 9.5 | 4.1–45.0 | 22.2 | 9.9–22.2 | 1 | 1–2 | 4 | 5–18 |
| CD19+CD27+CD38++CD20-(ASC) | 39.9 | 1.1–4.1 | 13.0 | 3.8–12.9 | 3 | 0–1 | 3 | 3–10 |
RBE: recent bone marrow emigrants; RTE: recent thymic emigrants; TCM: central memory T cells; TEM: effector memory T cells; TEMRA: terminally differentiated CD8+ cells; Treg: regulatory T cells; na: not available.
The number of MS controls on fingolimod and on fingolimod washout were 4 and 3, respectively.
a
The washout ranged from 14 to 29 days.
b
Values in healthy controls: RTE: 11.4–48.1% and 115–913/μL; RBE: 2.1–26.1% and 5–47 /μL; TEMRA: 5.2–63.5% and 22–467 μL; ASC: 0.2–8.1% and 0.3–22 μL; CD3 + CD4 + HLA-DR+: 1.6–12.2% and 15–123 μL; CD3 + CD8 + HLA-DR+: 2.7–31.7% and 17–346 μL.